NCT05829356View on ClinicalTrials.gov

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

PHASE1CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

March 14, 2024

Study Completion Date

March 14, 2024

Conditions
Influenza Immunization
Interventions
BIOLOGICAL

H3 mRNA / LNP Vaccine

"Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular"

BIOLOGICAL

Quadrivalent recombinant influenza Vaccine (RIV4)

"Pharmaceutical Form: Solution for injection in a pre-filled syringe~Route of Administration: Intra-Muscular"

Trial Locations (8)

3124

Investigational Site Number : 0360002, Camberwell

4006

Investigational Site Number : 0360004, Herston

4506

Investigational Site Number : 0360001, Morayfield

5000

Investigational Site Number : 0360003, Adelaide

LE1 5WW

Investigational Site Number : 8260002, Leicester

SW10 9NH

Investigational Site Number : 8260001, London

W12 0HS

Investigational Site Number : 8260004, London

S10 2JF

Investigational Site Number : 8260003, Sheffield

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY